Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 04ANKARA6279, Update and Next Steps on Pharmaceuticals Issues

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #04ANKARA6279.
Reference ID Created Released Classification Origin
04ANKARA6279 2004-11-05 11:44 2011-08-24 01:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Ankara
This record is a partial extract of the original cable. The full text of the original cable is not available.
UNCLAS SECTION 01 OF 02 ANKARA 006279 
 
SIPDIS 
 
DEPT FOR E, EB/TPP/MTA/IPC, EUR/ERA, EUR/SE 
USTR FOR LERRION/BPECK 
USEU FOR CHRIS WILSON 
USPTO FOR ELAINE WU 
USDOC FOR ITA/MAC/DDEFALCO 
 
SENSITIVE 
 
E.O. 12958: N/A 
TAGS: ETRD KIPR TU
SUBJECT: Update and Next Steps on Pharmaceuticals Issues 
in Turkey 
 
 
SENSITIVE BUT UNCLASSIFIED.  PLEASE HANDLE ACCORDINGLY. 
 
Ref: (A) Ankara 5695 (B) 2003 State 322108 
(C) Ankara 5385 
 
Summary 
------- 
 
1. (SBU) The research-based pharmaceuticals industry 
continues to grapple with a difficult set of challenges 
in the areas of intellectual property protection (lack 
of data exclusivity and potential patent infringement) 
and reimbursement reform (including non-transparent 
development of restrictive lists of eligible drugs).  In 
response to the EU's threat of WTO dispute settlement or 
even trade sanctions if Turkey continues to delay data 
exclusivity, it appears that the GOT is close to a 
decision to implement protection soon.  Washington 
agencies and Mission elements have actively advocated 
for the pharmaceuticals companies in the past and will 
continue to do so.  End Summary. 
 
Data Exclusivity 
---------------- 
 
2. (SBU) As reported ref A, the EC's Trade Barrier 
Report (TBR) found that Turkey has not complied with the 
customs union and TRIPS Agreement requirements on data 
exclusivity.  The EU threatened formal WTO consultations 
or trade sanctions if Turkey did not agree to implement 
these by the end of October 2004.  Industry sources tell 
us that this deadline has been extended by several 
weeks.  The Foreign Trade Undersecretary in October 
hosted a meeting with representatives of both the 
research-based and generic industries to discuss data 
exclusivity.  Pfizer representatives are cautiously 
optimistic that the GOT will ultimately agree to move 
forward implementation of data exclusivity (currently 
planned for end-2007), perhaps even to retroactive 
implementation.  A Dutch diplomat based in Ankara 
recently told us that there is interest in several EU 
member embassies in a joint demarche with the USG on 
this issue if the GOT does not come up with a 
satisfactory policy, as Washington had suggested last 
year (ref B), but we have not heard an authoritative 
view from the European Union delegation on this matter. 
 
Zyprexa 
------- 
 
3. (U) Eli Lilly is concerned that generic manufacturers 
have applied to the Health Ministry for registration of 
copies of Zyprexa, which has a valid Turkish patent 
which is not due to expire until 2016.  We have raised 
this issue with the GOT on several occasions (see 
below). 
 
Reimbursement System Reform and Drug Savings 
-------------------------------------------- 
 
4. (U) As part of its planned social security reform, 
one of the key structural reforms supported by the IMF 
and World Bank, the GOT is contemplating reforms in its 
pharmaceuticals reimbursement systems which will reduce 
health expenditures, but have a dramatic impact on the 
industry.  A "positive list" of drugs eligible for 
reimbursement, not yet approved by the GOT, could 
severely limit Turkish patient access to innovative 
products by restricting the types of physicians and 
facilities authorized to prescribe certain drugs. 
Research-based industry claims that it has not had 
sufficient opportunity to provide input into the 
development of this restrictive list.  It also objects 
to GOT pressure to provide significant discounts on drug 
prices. 
 
Recent Advocacy 
--------------- 
 
5. (SBU) Washington agencies and the Mission have 
advocated aggressively and at high levels on behalf of 
research-based industry, particularly over the data 
exclusivity issue.  Lack of data exclusivity was the 
primary reason for elevating Turkey to the Priority 
Watch List in the 2004 Special 301 Review.   Recent 
advocacy includes: 
 
- Commerce U/S Aldonas' October 29 letter to Foreign 
Trade Undersecretary Tuncer Kayalar; 
 
- The Ambassador raised the data exclusivity problem in 
an October 25 speech to the Izmir Chamber of Commerce on 
investment issues, as well as in his opening remarks at 
a September 9 conference for Turkish judges and 
prosecutors on intellectual property enforcement; 
 
- The Ambassador told State Minister Tuzmen that Turkey 
is not complying with its WTO TRIPS obligations on data 
exclusivity in a September 17 meeting (ref C); 
 
- Commerce DAS Stewart's September 9 meeting with the 
Health Ministry's General Director for Pharmaceuticals, 
the Deputy U/S Foreign Trade, and other GOT officials; 
 
- The Ambassador's August 19 letter to Health Minister 
Akdag urging that the Ministry not approve patent- 
infringing copies of Eli Lilly's Zyprexa drug. 
 
Next Steps 
---------- 
 
6. (SBU) Post sees results from our and EU pressure on 
GOT.  The dialog between Pharma companies and senior GOT 
officials seems to have improved.  We will continue to 
press the Turks to implement data exclusivity 
immediately, involve industry stakeholders fully in 
reimbursement reform, and refrain from approving generic 
copies of drugs which should enjoy patent protection. 
As noted above, Turkey's data exclusivity policy may 
improve in the near future in response to the EC's TBR 
report.  Mission has requested meetings with the Health 
Ministry U/S as well as the President of the Turkish 
Patent Institute on these issues.  We will also ensure 
that visiting economic officials are briefed and have 
the opportunity to raise pharmaceuticals issues with 
decisionmakers in the GOT.  We should also use the next 
Trade and Investment Framework Agreement (TIFA) meeting, 
likely to be held in early 2005 in Ankara, to further 
our objectives in this area. 
Edelman